Pulmonx
Developer and commercial provider of bronchoscopic assessment and treatment technologies for severe obstructive lung disease. Offers one-way endobronchial valve therapy and associated diagnostic and planning tools, cloud-based quantitative CT analysis, and clinician training programs. Operates globally and has generated clinical evidence from multiple randomized controlled trials and peer-reviewed publications. Headquartered in Redwood City, California and Neuchâtel, Switzerland.
Industries
Nr. of Employees
large (251-1000)
Patents
Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation
US-12705742-B2
View Details
Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation
US-12705742-B2
View DetailsProducts
One-way endobronchial valve for bronchoscopic lung volume reduction
An implantable one-way endobronchial valve designed to occlude airways feeding a hyperinflated lobe to promote lobar deflation and reduce hyperinflation in selected patients with severe emphysema/COPD.
Cloud-based quantitative lung analysis reports
CT-based analysis reports providing emphysema quantification, fissure completeness, and volumetric data to support clinical decision-making and target selection.
Catheter-based pulmonary assessment system
A catheter and console system that provides flow and pressure measurements for targeted lobes to assess collateral ventilation prior to valve placement.
StratX Lung
A cloud-based quantitative CT analysis service that supports Zephyr Valve patient selection and treatment targeting by providing information on emphysema destruction, fissure completeness, and lobar volumes.
Zephyr 4.0-LP
A low-profile implantable one-way endobronchial valve for deployment in shorter airways with a diameter range of 4.0 to 7.0 mm.
Zephyr 4.0 Delivery Catheter
An endobronchial delivery catheter sized for deploying Zephyr 4.0 valves.
One-way endobronchial valve for bronchoscopic lung volume reduction
An implantable one-way endobronchial valve designed to occlude airways feeding a hyperinflated lobe to promote lobar deflation and reduce hyperinflation in selected patients with severe emphysema/COPD.
Cloud-based quantitative lung analysis reports
CT-based analysis reports providing emphysema quantification, fissure completeness, and volumetric data to support clinical decision-making and target selection.
Catheter-based pulmonary assessment system
A catheter and console system that provides flow and pressure measurements for targeted lobes to assess collateral ventilation prior to valve placement.
StratX Lung
A cloud-based quantitative CT analysis service that supports Zephyr Valve patient selection and treatment targeting by providing information on emphysema destruction, fissure completeness, and lobar volumes.
Zephyr 4.0-LP
A low-profile implantable one-way endobronchial valve for deployment in shorter airways with a diameter range of 4.0 to 7.0 mm.
Zephyr 4.0 Delivery Catheter
An endobronchial delivery catheter sized for deploying Zephyr 4.0 valves.
Services
Cloud-based analysis that assesses emphysema distribution, fissure completeness, and lobar volumes to support target lobe selection prior to intervention.
Structured training including online modules, in-person and hands-on procedural training, case-based learning, and outcomes review to credential physicians and centers.
Maintained directory of assessment centers and trained physicians with listing criteria to facilitate referrals and patient access to assessment and treatment.
Cloud-based analysis that assesses emphysema distribution, fissure completeness, and lobar volumes to support target lobe selection prior to intervention.
Structured training including online modules, in-person and hands-on procedural training, case-based learning, and outcomes review to credential physicians and centers.
Maintained directory of assessment centers and trained physicians with listing criteria to facilitate referrals and patient access to assessment and treatment.
Expertise Areas
- Interventional pulmonology
- Bronchoscopic lung volume reduction
- Quantitative CT-based treatment planning
- Pulmonary physiologic assessment and testing
Key Technologies
- One-way endobronchial valves for bronchoscopic therapy
- Quantitative CT analysis and lung segmentation
- Catheter-based flow and pressure measurement systems
- Cloud-based analytics and reporting
News & Updates
Device received breakthrough status and FDA approval in June 2018 for bronchoscopic lung volume reduction as a less-invasive treatment option for severe emphysema.
More than 100 scientific articles and multiple randomized controlled trials, meta-analyses, and health-economics analyses reporting clinical benefits for the therapy.
Device received breakthrough status and FDA approval in June 2018 for bronchoscopic lung volume reduction as a less-invasive treatment option for severe emphysema.
More than 100 scientific articles and multiple randomized controlled trials, meta-analyses, and health-economics analyses reporting clinical benefits for the therapy.